Pullman Regional Hospital | |
835 S Bishop Blvd, Pullman, Washington 99163 | |
(509) 332-2541 | |
Name | Pullman Regional Hospital |
---|---|
Type | Critical Access Hospital |
Location | 835 S Bishop Blvd, Pullman, Washington |
Ownership | Government - Hospital District or Authority |
Emergency Services | Yes |
Medicare ID (CCN) | 501331 |
NPI Number | 1124266671 |
Organization Name | PULLMAN REGIONAL HOSPITAL |
Address | 1620 Se Summit Ct, Pullman, WA 99163 |
Hospital Type | Rehabilitation Hospital |
Phone Number | 509-332-5106 |
News Archive
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."
The Alzheimer's Drug Discovery Foundation announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.
Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.
Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.
› Verified 4 days ago
NPI Number | 1730498353 |
Organization Name | PULLMAN REGIONAL HOSPITAL |
Address | 1620 Se Summit Ct, Pullman, WA 99163 |
Hospital Type | General Acute Care Hospital |
Phone Number | 509-332-5106 |
News Archive
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."
The Alzheimer's Drug Discovery Foundation announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.
Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.
Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.
› Verified 4 days ago
Able to receive lab results electronically | Not Available |
Able to track patients' lab results, tests, and referrals electronically between visits | Not Available |
News Archive
YM BioSciences Inc., a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, announced that preclinical results for CYT997 were presented today in a poster by Cytopia Limited at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in Boston, Massachusetts.
"We are delighted to be working with such esteemed institutions in order to generate cutting-edge therapeutic antibodies," said Matthew Baker, chief scientific officer and co-founder of Antitope. "This agreement combines our partners' expertise in novel therapeutic strategies with Antitope's expertise in engineering humanized antibodies to create therapeutic antibodies that may have a significant impact on the treatment of these major diseases."
The Alzheimer's Drug Discovery Foundation announced six new investments totaling $6 million through its Diagnostics Accelerator initiative.
Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.
Celldex Therapeutics, Inc. announced today it will regain full worldwide rights to develop and commercialize rindopepimut (CDX-110), effective November 1, 2010.
› Verified 4 days ago
Pullman Regional Hospital Critical Access Hospital Location: 835 S Bishop Blvd, Pullman, Washington 99163 Phone: (509) 332-2541 |